Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M (2020) Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 70:299–312. https://doi.org/10.3322/caac.21613

Article  PubMed  Google Scholar 

Shan X, Fan X, Liu X, Zhao Z, Wang Y, Jiang T (2018) Clinical characteristics associated with postoperative seizure control in adult low-grade gliomas: a systematic review and meta-analysis. Neuro Oncol 20:324–331. https://doi.org/10.1093/neuonc/nox130

Article  PubMed  Google Scholar 

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro Oncol 4:iv1–iv62. https://doi.org/10.1093/neuonc/nov189

Article  Google Scholar 

Stupp R, Mason WP, Van D, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes AA, Marosi C, Bogdahn U (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

Article  CAS  PubMed  Google Scholar 

Zhu P, Du XL, Lu G, Zhu J-J (2017) Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. Oncotarget 8:44015–44031. https://doi.org/10.18632/oncotarget.17054

Article  PubMed  PubMed Central  Google Scholar 

Liu Y (2019) Diagnostic and Treatment Guidelines for Gliomas (2018 edition). Chin J Neurosurg 35:217–239. https://doi.org/10.3760/cma.j.issn.1001-2346.2019.03.001

Article  Google Scholar 

Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, Bao Z, Wang Y, Qiu X, Jiang T (2013) Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution. J Neurooncol 113:259–266. https://doi.org/10.1007/s11060-013-1103-9

Article  CAS  PubMed  Google Scholar 

Jiang T, Jin Q, Zhang Z, Zhang D, Li S, Qiao H, Zhang W, Wang Y, Li G, Fang S (2020) Analysis of prognostic factors and long-term postoperative follow-up in 1828 adult patients with newly diagnosed gliomas in the cerebral hemisphere. Chin J Neurosurg 36:706–711. https://doi.org/10.3760/cma.j.cn112050-20200409-00225

Article  Google Scholar 

Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ (2020) Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18:1537–1570. https://doi.org/10.6004/jnccn.2020.0052

Article  PubMed  Google Scholar 

CtotCGfDaToCNS G (2016) Chinese Guidelines for Diagnosis and Treatment of Central Nervous System Glioma (2015). Chin Med J 96:25. https://doi.org/10.3760/cma.j.issn.0376-2491.2016.07.003

Article  Google Scholar 

Jiang T, Nam D, Ram Z, Poon W, Wang J, Boldbaatar D, Mao Y, Ma W, Mao Q, You Y (2021) Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett 499:60–72. https://doi.org/10.1016/j.canlet.2020.10.050

Article  CAS  PubMed  Google Scholar 

Burri SH, Gondi V, Brown PD, Mehta MP (2018) The evolving role of tumor treating fields in managing glioblastoma: guide for oncologists. Am J Clin Oncol 41:191–196. https://doi.org/10.1097/COC.0000000000000395

Article  PubMed  Google Scholar 

Riley MM, San P, Lok E, Swanson KD, Wong ET (2019) The clinical application of tumor treating fields therapy in glioblastoma. J Vis Exp 146:e58937. https://doi.org/10.3791/58937

Article  CAS  Google Scholar 

Rick J, Chandra A, Aghi MK (2018) Tumor treating fields: a new approach to glioblastoma therapy. J Neurooncol 137:447–453. https://doi.org/10.1007/s11060-018-2768-x

Article  PubMed  Google Scholar 

Guzauskas GF, Pollom EL, Stieber VW, Wang BC, Garrison LP Jr (2019) Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. J Med Econ 22:1006–1013. https://doi.org/10.1080/13696998.2019.1614933

Article  PubMed  Google Scholar 

Chen C, Xu H, Song K, Zhang Y, Zhang J, Wang Y, Sheng X, Chen L, Qin Z (2022) Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center. J Clin Med 11:5855. https://doi.org/10.3390/jcm11195855

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porter KR, McCarthy BJ, Berbaum ML, Davis FG (2011) Conditional survival of all primary brain tumor patients by age, behavior, and histology. Neuroepidemiology 36:230–239. https://doi.org/10.1159/000327752

Article  PubMed  PubMed Central  Google Scholar 

Shi F, Shang Y, Rui M, Ma A (2020) Application of SurvHE Package of R for Health Economic Evaluation. Chinese Health Economics 39:9–14. https://doi.org/10.7664/CHE20200902

Article  Google Scholar 

He X, Aixia M (2020) Discussion on simulation method of survival curve of tumor immunotherapy in pharmacoeconomics. Chinese Health Economics 39:58–61. https://doi.org/10.7664/CHE20201014

Article  Google Scholar 

Yaozh.com (2023) Drug bidding information database. Yaozh.com. https://db.yaozh.com/. Accessed 11 March 2023

Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B (2018) Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell 175:1665–1678. https://doi.org/10.1016/j.cell.2018.09.038

Article  CAS  PubMed  Google Scholar 

Liu G (2020) China Guidelines for Pharmacoeconomic Evaluations 2020 Edition. China Market Press, Peking

Google Scholar 

Jiang Y, Wang X (2022) Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China. Eur J Hosp Pharm 29:139–144. https://doi.org/10.1136/ejhpharm-2020-002208

Article  PubMed  Google Scholar 

Liu G, Kang S, Wang X (2021) Pharmacoeconomic Evaluation of Pembrolizumab in First-line Treatment of Advanced Non-small Cell Lung Cancer with High PD-L1 Expression. Chin Pharm 32:1351–1356. https://doi.org/10.6039/j.issn.1001-0408.2021.11.12

Article  Google Scholar 

Wumaier K, Li W, Chen N, Cui J (2021) Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis. Thromb J 19:68. https://doi.org/10.1186/s12959-021-00319-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu X (2019) Health economics analysis of phenobarbital in treating epilepsy in primary health institutions. Diet and Health Care 6(44):270–271

Google Scholar 

Wu B, Zhang Q, Sun J (2018) Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. J Immunother Cancer 6:124. https://doi.org/10.1186/s40425-018-0440-9

Article  PubMed  PubMed Central  Google Scholar 

Zhang D, Li X, Ding J, Ke X, Ding W, Ren Y, Xu H, Li H, Ma A, Tang W (2021) Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis. Front Public Health 9:670108. https://doi.org/10.3389/fpubh.2021.670108

Article  PubMed  PubMed Central  Google Scholar 

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K (2007) The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 11:iii–iv. https://doi.org/10.3310/hta11450

Article  PubMed  Google Scholar 

Dryhurst S, Schneider CR, Kerr J, Freeman ALJ, Recchia G, van der Bles AM, Spiegelhalter D, van der Linden S (2020) Risk perceptions of COVID-19 around the world. J Risk Res 23:994–1006. https://doi.org/10.1080/13669877.2020.1758193

Article  Google Scholar 

Hatswell AJ, Bullement A, Briggs A, Paulden M, Stevenson MD (2018) Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. Pharmacoeconomics 36:1421–1426. https://doi.org/10.1007/s40273-018-0697-3

Article  PubMed  Google Scholar 

Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X (2016) The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 18:1129–1136. https://doi.org/10.1093/neuonc/now102

Article  CAS  PubMed  PubMed Central  Google Scholar